Raymond James Financial Cuts Abbott Laboratories (NYSE:ABT) Price Target to $130.00

Abbott Laboratories (NYSE:ABT) had its price objective cut by stock analysts at Raymond James Financial from $146.00 to $130.00 in a report released on Friday,MarketScreener reports. The brokerage currently has an “outperform” rating on the healthcare product maker’s stock. Raymond James Financial’s price target would indicate a potential upside of 19.61% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Daiwa Capital Markets upped their target price on Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. The Goldman Sachs Group lowered their price objective on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a report on Friday. Barclays boosted their target price on shares of Abbott Laboratories from $162.00 to $169.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Sanford C. Bernstein boosted their price objective on Abbott Laboratories from $150.00 to $154.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Finally, BTIG Research dropped their target price on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $143.37.

Abbott Laboratories Stock Up 0.1%

ABT traded up $0.08 during midday trading on Friday, hitting $108.69. The company had a trading volume of 2,307,181 shares, compared to its average volume of 8,972,974. The company has a market capitalization of $189.00 billion, a price-to-earnings ratio of 13.65, a PEG ratio of 2.00 and a beta of 0.72. The stock’s 50 day moving average price is $125.23 and its 200 day moving average price is $128.54. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 52 week low of $105.78 and a 52 week high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period last year, the business posted $1.34 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Abbott Laboratories

A number of hedge funds have recently made changes to their positions in the business. IMG Wealth Management Inc. increased its holdings in Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after buying an additional 167 shares during the last quarter. Harbor Capital Advisors Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $27,000. Cloud Capital Management LLC purchased a new position in Abbott Laboratories in the third quarter valued at approximately $29,000. Guerra Advisors Inc purchased a new stake in Abbott Laboratories in the third quarter worth $31,000. Finally, Anfield Capital Management LLC raised its stake in shares of Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after buying an additional 104 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Several sell‑side analysts kept constructive ratings and still see meaningful upside — Piper Sandler cut its price target to $135 but remains “overweight,” and BTIG trimmed its target to $140 while keeping a “buy” call, signaling continued analyst confidence despite the pullback. Benzinga
• Positive Sentiment: Med tech (devices) and Established Pharmaceuticals delivered strong growth (double‑digit devices, mid‑single to high single pharma), which management says helped offset weakness in other segments and supports the company’s multi‑year growth thesis. Blockonomi
• Positive Sentiment: Market commentators view the pullback as a potential buying opportunity for long‑term investors because Abbott remains a cash‑generative Dividend King with capacity for buybacks and continued margin improvement. MarketBeat
• Neutral Sentiment: Adjusted EPS of $1.50 matched consensus, showing underlying earnings resilience even as revenues lagged; GAAP results included items that lowered headline net income. Press Release
• Neutral Sentiment: Company guidance: Q1 2026 adjusted EPS of $1.120–1.180 (below the ~1.20 consensus) and FY 2026 adjusted EPS of $5.55–5.80 (around consensus). Guidance tempered near‑term expectations but keeps mid/longer‑term growth intact. Press Release
• Negative Sentiment: Revenue missed Street estimates (~$11.46–11.5B reported vs. ~$11.8–11.9B expected); the Nutrition business declined sharply (near‑9% year‑over‑year) and Diagnostics weakened (lower COVID testing and volatility), which triggered the market sell‑off. Reuters Blockonomi
• Negative Sentiment: Unusual bearish positioning: intraday put option volume spiked sharply, indicating heavy hedging or speculative bearish bets that can amplify downward price moves. (Reported market activity)
• Negative Sentiment: Regulatory/legal overhang: documents show India regulators are scrutinizing supply of a codeine‑based cough syrup tied to abuse investigations, introducing potential reputational and compliance risk. Reuters

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.